Lecanemab (Leqembi) for the Slowing of Alzheimer Disease

Megan L. Hull; Megan Adelman

Hypertrophic Nodules on the Knuckles

Jun 2025

Inappropriate Use of Oral Antiplatelet Drugs

STEPS

New Drug Reviews

Lecanemab (Leqembi) for the Slowing of Alzheimer Disease

Megan L. Hull, PharmD, BCACP

Megan Adelman, PharmD, BCPS, BCGP, CDCES

American Family Physician. 2025;111(6):549-550.

Author disclosure: No relevant financial relationships.

MEGAN L. HULL, PHARMD, BCACP, OhioHealth Grant Family Medicine, Columbus

MEGAN ADELMAN, PHARMD, BCPS, BCGP, CDCES, Cleveland Clinic Akron General Center for Family Medicine, Akron, Ohio

Address correspondence to Megan L. Hull, PharmD, BCACP, at megan.hull@ohiohealth.com.

Author disclosure: No relevant financial relationships.

1.DailyMed. Drug label information. Leqembi–lecanemab injection, solution. Updated January 27, 2025. Accessed March 26, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975
2.Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.
3.van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9-21.
4.Ebell MH, Barry HC, Baduni K, et al. Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis. Ann Fam Med. 2024;22(1):50-62.
5.National Institute for Health and Care Excellence. Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS. August 22, 2024. Accessed September 16, 2024. https://www.nice.org.uk/news/articles/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.